CARTPT and neoplasm: A TGF-beta 2 receptor knockout CART, developed using the CRISPR/Cas9 system, was found to reduce Treg-induced conversion, prevent CART exhaustion, improve in vivo elimination of tumor and improve CART memory subset formation to improve long-term efficacy [208].